25Oct/13

What's Behind AbbVie's Rocking Q3 Earnings – Motley Fool


Jutia Group

What’s Behind AbbVie’s Rocking Q3 Earnings
Motley Fool
AbbVie’s partnership with Biogen Idec (NASDAQ: BIIB ) on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that
AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call Seeking Alpha
AbbVie Reports Third-Quarter 2013 Financial ResultsMarketWatch

all 25 news articles »

25Oct/13

High-Risk Organs From Deceased Donors Safe When Screened with Current … – Infection Control Today


Counsel & Heal

High-Risk Organs From Deceased Donors Safe When Screened with Current
Infection Control Today
Approximately 10 percent of deceased donor kidneys are considered “high-risk” for infection (HIV, HCV, HBV) and disease transmission according to criteria set by the Centers for Disease Control and Prevention. But new research suggests that many of
Some ‘High-Risk’ Kidneys May Be Safe for Organ Transplant: StudyHealthDay

all 4 news articles »

25Oct/13

'High-risk' organs from deceased donors safe when screened with current methods – Medical Xpress

‘High-risk’ organs from deceased donors safe when screened with current methods
Medical Xpress
Approximately 10% of deceased donor kidneys are considered “high-risk” for infection (HIV, HCV, HBV) and disease transmission according to criteria set by the Centers for Disease Control and Prevention. But new research suggests that many of these 

and more »